SCI-210

PreclinicalSmall molecule

NNeurothera Labs Inc.

SCI-210 is one of 38 small molecule programs targeting Autism Spectrum Disorder. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autism Spectrum DisorderActive, not recruiting

Autism Spectrum DisorderPreclinical

Active, not recruiting

Competition

Competitive Landscape

160 competitors in Autism Spectrum Disorder

#DrugCompanyPhaseTrials

Vraylar

AbbVie

Phase 3

2 2

Elavil

AstraZeneca

Phase 3

1 3

Bumex

VValidus Pharmaceuticals

Phase 3

3 4

Rexulti

Otsuka

Phase 3

2 5

Nuplazid

AACADIA Pharmaceuticals Inc.

Phase 3

2 6

Glucophage

EMD Serono

Phase 3

1 7

Hetlioz

VVanda Pharmaceuticals

Phase 3

1 8

Lithobid

SSolvay Pharmaceuticals

Phase 3

1 9

Circadin

NNeurim Pharmaceuticals Ltd.

Karx-EC

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Autism Spectrum Disorder1 trial

SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)

Recruiting·NNeurothera Labs Inc.·N/A·NCT05182697·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SCI-210. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SCI-210 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SCI-210. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Neurothera Labs Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNeurothera Labs Inc.

SCI-210

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Autism Spectrum Disorder1 trial

References

Drug Info

Quick Facts

Related News